This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Investors Twice Shy on Cell Therapeutics

Cell Therapeutics (CTIC - Get Report) has one approved cancer drug on the market with decent, albeit not huge, sales; two other experimental cancer drugs are involved in late-stage, pivotal clinical studies. What's a portfolio like this worth to Wall Street?

Biotech investors have certainly awarded other, similarly positioned companies market valuations of around $1 billion. Onyx Pharmaceuticals (ONXX), which has just a single cancer drug in phase III studies, sports a market cap of $1.3 billion. Telik (TELK) has a bit more going on in its drug pipeline, although investors are only really focused on a single product in phase III studies. Market value: $945 million.

So, what gives with Cell Therapeutics? The Seattle biotech firm tallies a paltry market value of just $296 million. The stock closed Wednesday down 61 cents, or 9%, to $5.89 -- a new 52-week low. At that price, Cell Therapeutics is off 38% year to date and 50% in the past 12 months -- that's a wide underperformance relative to its biotech peers any way you slice it.

Let's just say that investors, when it comes to Cell Therapeutics, are in a serious "show-me" mood. You can lay part of the blame on a listless market that's not whetting anyone's appetite for added biotech risk. However, Cell Therapeutics has a history of overpromising and underperforming. Investors are likely to wait for documented good news from this company -- and not just happy talk from executives and analysts -- before they hop back on the investing wagon.

On Wednesday, the company announced plans to sell 8 million shares in a follow-on offering, a move that will further dilute current shareholders and is not likely to boost the company's stock price anytime soon.

Cell Therapeutics executives could not be reached for comment.

The showpiece of Cell Therapeutics' cancer drug pipeline is Xyotax, a reformulation of the blockbuster chemotherapy agent paclitaxel, sold for years by Bristol-Myers Squibb (BMY - Get Report) as Taxol before it went generic.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs